Minneapolis
89°F
eEdition
News & Politics
Sports
Food & Culture
Business
Outdoors
Opinion
Things To Do
Obituaries
More of What Matters to Minnesota
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Minnesota State Top Stocks
Markets
Minnesota Stocks
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Ambrx Biopharma Inc ADR
(NY:
AMAM
)
N/A
UNCHANGED
Last Price
Updated: 7:00 PM EDT, Mar 16, 2023
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Ambrx Biopharma Inc ADR
< Previous
1
2
3
4
5
6
7
8
9
Next >
3 Dividend Stocks That Are Too Good to Ignore: Q1 Edition
February 26, 2024
Here are the three dividend stocks that will never disappoint you. Buy them while they trade at a discount.
Via
InvestorPlace
3 Stocks to Buy That Are Up 200% or More in 2024
February 23, 2024
Each of these stocks up 200% in 2024 offer unique upside opportunities for investors, including equity arbitrage plays.
Via
InvestorPlace
The 3 Biotech Stocks That Could Make Your February Unforgettable
February 15, 2024
After a blistering hot year of biotech M&A, we’ll see more of the same in 2024. That could be great news for these hot biotech stocks.
Via
InvestorPlace
AMBRX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Ambrx Biopharma, Inc. - AMAM
February 10, 2024
From
Kahn Swick & Foti, LLC
Via
Business Wire
Looking Into Ambrx Biopharma's Recent Short Interest
January 29, 2024
Via
Benzinga
Assessing Ambrx Biopharma: Insights From 7 Financial Analysts
January 09, 2024
Via
Benzinga
Health Care Company Johnson & Johnson Announces Merger With Ambrx Biopharma
January 08, 2024
Via
Benzinga
Analyst Ratings for Ambrx Biopharma
November 14, 2023
Via
Benzinga
Better Growth Stock: UnitedHealth Group vs. Johnson & Johnson
January 27, 2024
These companies have been focusing on growing their operations, but which stock is likely to provide investors with better returns?
Via
The Motley Fool
Johnson & Johnson Secures Complete FDA Approval For Bladder Cancer Drug Balversa, After Almost Five Years Of Accelerated Approval
January 22, 2024
FDA-approved Balversa for urothelial carcinoma treatment. The first oral FGFR kinase inhibitor offers clinical benefits, extended overall survival, and a breakthrough for FGFR alterations in metastatic...
Via
Benzinga
Exposures
Product Safety
Johnson & Johnson's Q4 Earnings: Spotlight On Dividend Security Following Kenvue Split, Legal Costs, Acquisitions
January 22, 2024
Johnson & Johnson (JNJ) to report Q4 earnings on Jan. 23, with expectations of $2.28 EPS and $20.99B revenue. Strong, diverse company with reliable dividend, but impacted by talc lawsuit settlement and...
Via
Benzinga
Topics
Lawsuit
Exposures
Financial
Legal
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Ambrx Biopharma, Inc. (Nasdaq – AMAM), Gracell Biotechnologies Inc. (Nasdaq – GRCL), Axonics, Inc. (Nasdaq - AXNX), Harpoon Therapeutics, Inc. (Nasdaq - HARP)
January 16, 2024
From
Brodsky & Smith LLC
Via
GlobeNewswire
Week In Review: China Biopharmas Book $9 Billion In Deals During JP Morgan Conference Week
January 13, 2024
Shanghai Argo Biopharma entered 2 agreements with Novartis, out-licensing four next-gen RNAi therapeutics for $185 million upfront and a total value of $4.2 billion. Additionally, Ambrx Biopharma will...
Via
Talk Markets
Stock Market Rally Rebounds; Nvidia, Tesla, JPMorgan, Bitcoin ETFs In Focus: Weekly Review
January 12, 2024
The major indexes and leading stocks rebounded. Bitcoin ETFs fell in their debut.
Via
Investor's Business Daily
Topics
ETFs
AMBRX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Ambrx Biopharma, Inc. - AMAM
January 10, 2024
From
Kahn Swick & Foti, LLC
Via
Business Wire
Global Oncology Cancer Drugs Market Revenue Projected To Surpass $289 Billion By 2030
January 09, 2024
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:AMGN),(NASDAQ:AMAM),(NASDAQ:ELEV),(NASDAQ:NKTX) EQNX::TICKER_END
Via
FinancialNewsMedia
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Ambrx Biopharma, Inc. (Nasdaq – AMAM), Gracell Biotechnologies Inc. (Nasdaq – GRCL), Axonics, Inc. (Nasdaq - AXNX), Harpoon Therapeutics, Inc. (Nasdaq - HARP)
January 08, 2024
From
Brodsky & Smith LLC
Via
GlobeNewswire
Global Oncology Cancer Drugs Market Revenue Projected To Surpass $289 Billion By 2030
January 09, 2024
From
FN Media Group LLC
Via
GlobeNewswire
Dow Surges Over 100 Points; Commercial Metals Posts Upbeat Q1 Results
January 08, 2024
U.S. stocks traded higher toward the end of trading, with the Dow Jones index gaining more than 100 points on Monday. The Dow traded up 0.35% to 37,596.43 while the NASDAQ rose 1.89% to 14,799.21. The...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Why RxSight Shares Are Trading Higher By 20%? Here Are Other Stocks Moving In Monday's Mid-Day Session
January 08, 2024
Shares of RxSight, Inc. (NASDAQ: RXST) rose sharply during Monday’s session after the company issued preliminary FY23 and FY24 revenue guidance above estimates. Also, Needham maintained a Buy rating on...
Via
Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
January 08, 2024
Via
Benzinga
Crude Oil Falls Sharply; Ambrx Biopharma Shares Spike Higher
January 08, 2024
U.S. stocks traded mixed midway through trading, with the Nasdaq Composite gaining more than 1% on Monday. The Dow traded down 0.19% to 37,396.28 while the NASDAQ rose 1.20% to 14,698.88. The S&P 500...
Via
Benzinga
Topics
Stocks
Exposures
Fossil Fuels
US Equities
Why Is Ambrx Biopharma (AMAM) Stock Up 100% Today?
January 08, 2024
With Johnson & Johnson buying out Ambrx Biopharma, the win-win deal boosted AMAM stock while better positioning J&J’s oncology unit.
Via
InvestorPlace
Today Is Cancer-Focused Deals Day: Johnson & Johnson Scoops Up Ambrx Biopharma As Merck Boosts Cancer Portfolio With Harpoon Deal
January 08, 2024
Monday, Johnson & Johnson (NYSE: JNJ) has agreed to acquire Ambrx Biopharma Inc (NASDAQ: AMAM) in an all-cash merger transaction for a total equity value of approximately $2.0 billion, or $1.9 billi
Via
Benzinga
US Stocks Mixed; Nasdaq Jumps Over 100 Points
January 08, 2024
U.S. stocks traded mixed this morning, with the Nasdaq Composite gaining around 100 points on Monday. Following the market opening Monday, the Dow traded down 0.45% to 37,296.85 while the NASDAQ rose...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
J&J, Merck, Boston Scientific Debut Trio Of Splashy Takeovers Topping $3 Billion In Value
January 08, 2024
The year's biggest medical conference kicked off with a melee of buyout news.
Via
Investor's Business Daily
AMAM Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Ambrx Biopharma, Inc. Is Fair to Shareholders
January 08, 2024
From
Halper Sadeh LLC
Via
Business Wire
12 Health Care Stocks Moving In Monday's Pre-Market Session
January 08, 2024
Via
Benzinga
Biggest Short Squeeze Stocks Of The Week: Biotech Stocks Dominate, A Bitcoin-Related Stock Moves Up Leaderboard
November 06, 2023
Potential short squeeze plays gained steam in 2021, continued throughout 2022 and remained a focus of traders looking for the next big move. High short interest and steep borrowing costs are among the...
Via
Benzinga
Biggest Short Squeeze Stocks Of The Week: Two Biotech Stocks Move Up To Top The List
October 31, 2023
Potential short squeeze plays gained steam in 2021, continued throughout 2022, and remain a focus of traders looking for the next huge move. High short interest and steep borrowing costs are among the...
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.